Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Precision medicine for prostate cancer

Galazi, Myria, Rodriguez-Vida, Alejo, Ng, Tony, Mason, Malcolm David and Chowdhury, Simon 2014. Precision medicine for prostate cancer. Expert Review of Anticancer Therapy 14 (11) , pp. 1305-1315. 10.1586/14737140.2014.972948

Full text not available from this repository.


Metastatic castration-resistant prostate cancer remains a lethal disease despite considerable progress in systemic therapy over the past decade. The recent advances in genomic sequencing have improved the molecular classification of prostate cancer. The translation of genomic data into clinically relevant prognostic and predictive biomarkers to guide therapy is still in its infancy and therapies for castration-resistant prostate cancer are still used empirically. We discuss these genomic aberrations in more detail, focusing on androgen receptor signaling, ETS transcription factor gene rearrangements and PTEN loss. The incorporation of this genomic data within early phase clinical trials is evolving and may prove significant in advancing personalized care in prostate cancer.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher: Taylor and Francis
ISSN: 1473-7140
Last Modified: 25 Apr 2019 14:10

Citation Data

Cited 3 times in Google Scholar. View in Google Scholar

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item